Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cytovale

Explore full profile

Medical technology company dedicated to revolutionizing diagnostics using cell mechanics and machine learning

South San Francisco, United StatesFounded 2013Biotech & Life Sciences
Valuation $500M–1B Last recorded · 2024
Headcount 100–500 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Cytovale and the history behind them.

About Cytovale

Cytovale is a medical technology startup that operates in the healthcare sector, specifically in the field of diagnostics for fast-moving diseases. The company's primary focus is on sepsis, a potentially life-threatening condition caused by the body's response to an infection. Cytovale's flagship product, IntelliSep, is designed to provide rapid, reliable sepsis diagnosis in less than 10 minutes, a significant improvement over traditional methods that can take hours or even days.

The company's technology, known as the Cytovale system, uses host response technology to analyze thousands of cells per second. This allows it to quickly assess the state of a patient's immune system and identify disease signatures. This information can then be used by clinicians to aid in diagnosis and inform treatment decisions.

Cytovale's business model is based on selling its IntelliSep system to healthcare providers. The system offers a simple workflow with minimal hands-on time, making it an attractive option for busy healthcare settings. By providing actionable information quickly, the system can potentially improve patient outcomes and reduce healthcare costs, both of which are key selling points for potential clients.

In summary, Cytovale is a promising startup in the medical technology sector, offering a rapid, reliable solution for sepsis diagnosis. Its innovative technology and business model position it well for success in the healthcare market.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2013
Headquarters
South San Francisco, United States
Employees
122
Open positions
2
Dealroom signal
74.2/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotech & Life Sciences, Analytics, Biotechnology, Core AI, Spinout, Biotech and Pharma, AI Applications
Technology
Artificial Intelligence, Deep Tech, Machine Learning
Business model
Manufacturing
Client focus
b2c

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Oct 2024 $100M $400M CPP Investments · Global Health Investment Corporation · Breakout Ventures · Norwest Venture Partners ↗
SERIES COther financing Nov 2023 $84M $336M Sands Capital Management · Global Health Investment Corporation · Norwest Venture Partners ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Cytovale website traffic

Latest recorded traffic for Cytovale is 8.6K monthly website visits, up 7.5% over the last three months. Cytovale's team declined 6.2% over the past year.

Latest monthly visits8.6K 3-month web change+7.5% 1-year team growth-6.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • US National Science Foundation

Series A4 investors entered at this stage

  • Dolby Family Ventures
  • Blackhorn Ventures
  • Breakout Ventures
  • GRIDS Capital

Series B and later5 investors entered at this stage

Other known investors2 additional known investors

  • Google for Startups Accelerator
  • University of California, Los Angeles
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States97.3%
🇬🇧 United Kingdom1.8%
🇦🇺 Australia0.9%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cytovale on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cytovale’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.